Skip to main content

Table 1 Patients’ baseline characteristics

From: Fluorescence optical imaging and musculoskeletal ultrasonography in juvenile idiopathic polyarticular disease before and during antirheumatic treatment - a multicenter non-interventional diagnostic evaluation

 

All patients (n = 37)

DMARD cohort (n = 24)

Biologics cohort (n = 13)

Male/female

7/30

5/19

2/11

Age (years)

13.9 (2.2)

14.3 (2.1)

13.5 (2.4)

Disease duration (years)

3.6 (3.2)

3.2 (4.1)

4.1 (3.7)

CHAQ-DI

0.61 (0.7)

0.54 (0.58)

0.66 (0.84)

JADAS 10

16.9 (5.7)

15.5 (5.6)

19.0 (5.0)

ESR (mm/h)

17.6 (20.1)

18.9 (21.8)

14.4 (15)

CRP(mg/l)

5.0 (12.2)

2.7 (4.5)

8.7 (18.3)

Physician Global Assessment VAS (cm)

4.8 (2.1)

4.4 (1.8)

5.5 (2.3)

Parents Global Assessment VAS (cm)

4.5 (2.5)

4.5 (2.1)

4.5 (3.2)

Number of active joints

7.1 (5.2)

6.7 (5.2)

8.3 (5.0)

Number of tender joints

9.6 (8.9)

9.6 (8.0)

10.0 (11.4)

Number of swollen joints

7.2 (5.7)

6.8 (5.7)

8.1 (5.5)

Number of joints with LOM

6.5 (6.7)

5.4 (5.3)

8.4 (8.4)

  1. Data presented as number or mean (standard deviation)
  2. DMARD disease-modifying antirheumatic drug, CHAQ Childhood Health Assessment Questionnaire, CRP C-reactive protein, ESR erythrocyte sedimentation rate, JADAS Juvenile Diseases Activity Score, LOM limitation of motion, VAS visual analog scale